INSIDERFilingvia Quantisnow
Surface Oncology Inc. logo

Surface Oncology (SURF) executive Ross sold 16,713 shares for $15.7K at $0.94

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Robert W. Ross (executive at Surface Oncology Inc., SURF) reported that they sold 16,713 shares for $15.7K at $0.94 on Aug 1, 2023. After these transactions the filing shows 83,193 shares held directly.

Reporting person
Ross Robert W.
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Aug 1, 2023Open-market sale (S)Common Stock1-16,713$0.94$15.7K83,193 direct

Holdings before and after

  • Common Stock: 99,906 to 83,193 direct

Footnotes from the filing

  1. 1. Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units.

Transaction codes in this filing

Open-market sale:
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

FAQ

What did Ross report in this SURF Form 4?

Robert W. Ross (executive at Surface Oncology Inc., SURF) reported that they sold 16,713 shares for $15.7K at $0.94 on Aug 1, 2023. After these transactions the filing shows 83,193 shares held directly.

How many SURF shares does Ross hold after this filing?

The filing shows 83,193 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

Was this SURF insider sale made under a 10b5-1 plan?

The filing's footnotes do not mention a Rule 10b5-1 trading plan.

What does transaction code S mean on an SEC Form 4?

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Historical context for SURF

Earlier insider filings at SURF

Quantisnow market dataNASDAQ
Surface Oncology Inc. logo
SURF
Surface Oncology Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2018
Get push alerts for SURF

Follow SURF and get a push notification the moment its next story breaks.

Full SURF profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SURF (Surface Oncology Inc.) and more on Quantisnow.